{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:35:36Z","timestamp":1772991336796,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this study, we aimed to evaluate HLA-B subtypes in cases developing TB while using anti-TNF agents and to compare with the HLA-B subtypes of three different groups including community-acquired TB cases, anti-TNF patients without TB and healthy controls. The study consisted of four groups. Group 1: 35 community-acquired TB patients, group 2; 47 anti-TNF-TB patients, group 3; 61 anti-TNF (non TB) patients and group 4; 40 healthy controls. HLA-B subgroups were studied genetically from blood samples taken from the patients. Approval was received from the ethics committee. HLA-B typing was performed by using the LIFECODES HLA-B eRES SSO Typing SSO typing kit (Immucor, Stamford, CT, USA). Among HLA-B subtypes, significant differences between the four groups were found only for HLA-B5, HLA-B8, HLA-B27 and HLA-B38. Although frequency of HLA-B8 was highest in patients developing TB during anti-TNF treatment, significance was lost after Bonferoni correction. HLA-B27 was significantly higher in both anti-TNF groups, with and without TB, due to presence of patients with ankylosing spondylitis in those groups. To our knowledge, this is the first study analyzing HLA-B subtypes in anti-TNF patients developing TB. Although in literature HLA-B8 positivity was suggested to associate with or to confer a risk for community-acquired TB, we could not confirm this association in anti-TNF patients developing TB. However, further studies with larger number of patients from different ethnic groups are clearly needed to get the final word in this topic.<\/jats:p>","DOI":"10.1038\/s41598-025-00290-1","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:27:29Z","timestamp":1745972849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HLA B subtype analysis in patients developing tuberculosis during anti-TNF treatment"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-3896","authenticated-orcid":false,"given":"Fatih","family":"Albayrak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7289-1816","authenticated-orcid":false,"given":"G\u00f6khan","family":"Keser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-6521","authenticated-orcid":false,"given":"Serdar","family":"Oztuzcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0298-4157","authenticated-orcid":false,"given":"Belk\u0131s Nihan","family":"Co\u015fkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7054-5351","authenticated-orcid":false,"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-0591","authenticated-orcid":false,"given":"Tuba Demirci","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6k\u00e7e Kenar","family":"Art\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9680-7535","authenticated-orcid":false,"given":"G\u00f6zde \u00c7etin","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-9098","authenticated-orcid":false,"given":"B\u00fcnyamin","family":"K\u0131sac\u0131k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"5","key":"290_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00296-019-04276-x","volume":"39","author":"HN Lee","year":"2019","unstructured":"Lee, H. N. et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-\u03b1 agents in patients with rheumatoid arthritis: a retrospective chart review analysis. Rheumatol. Int. 39(5), 859\u2013868. https:\/\/doi.org\/10.1007\/s00296-019-04276-x (2019).","journal-title":"Rheumatol. Int."},{"issue":"3","key":"290_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00296-019-04510-6","volume":"40","author":"HW Kim","year":"2020","unstructured":"Kim, H. W., Kwon, O. C., Han, S. H. & Park, M. C. Positive conversion of interferon-\u03b3 release assay in patients with rheumatic diseases treated with biologics. Rheumatol. Int. 40(3), 471\u2013479. https:\/\/doi.org\/10.1007\/s00296-019-04510-6 (2020).","journal-title":"Rheumatol. Int."},{"issue":"3","key":"290_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3899\/jrheum.150177","volume":"43","author":"B Kisacik","year":"2016","unstructured":"Kisacik, B. et al. Characteristics predicting tuberculosis risk under tumor necrosis Factor-\u03b1 inhibitors: Report from a large multicenter cohort with high background prevalence. J. Rheumatol. 43(3), 524\u2013529. https:\/\/doi.org\/10.3899\/jrheum.150177 (2016).","journal-title":"J. Rheumatol."},{"issue":"9","key":"290_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/tmi.12923","volume":"22","author":"H Van Tong","year":"2017","unstructured":"Van Tong, H., Velavan, T. P., Thye, T. & Meyer, C. G. Human genetic factors in tuberculosis: An update. Trop. Med. Int. Health. 22(9), 1063\u20131071. https:\/\/doi.org\/10.1111\/tmi.12923 (2017).","journal-title":"Trop. Med. Int. Health"},{"key":"290_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon, W. G. et al. BSR biologics register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British society for rheumatology biologics register.(BSRBR). Ann. Rheum. Dis. 69, 522\u2013528 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"290_CR6","unstructured":"World Health Organization. Global tuberculosis report 2015. [Internet. Accessed November 4. ] (2015). Available from: www.who.int\/tb\/publications\/global_report\/en"},{"key":"290_CR7","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E. & Beenhouwer, D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261\u20131265 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"290_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/jmg.20.3.220","volume":"20","author":"SS Papiha","year":"1983","unstructured":"Papiha, S. S., Agarwal, S. S. & White, I. Association between phosphoglucomutase (PGM) and tuberculosis. J. Med. Genet. 20, 220 (1983).","journal-title":"J. Med. Genet."},{"key":"290_CR9","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.4049\/jimmunol.168.7.3394","volume":"168","author":"ML Olleros","year":"2002","unstructured":"Olleros, M. L. et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis Bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin. J. Immunol. 168, 3394\u20133401 (2002).","journal-title":"J. Immunol."},{"key":"290_CR10","doi-asserted-by":"crossref","unstructured":"Khomenko, A.G., Litvinov, V.I., Chukanova, V.P., Pospelov, L.E. Tuberculosis in patients with various HLA phenotypes. Tubercle 71, 187\u2013192 (1990).","DOI":"10.1016\/0041-3879(90)90074-I"},{"key":"290_CR11","unstructured":"Teran, L., Selman, M., Mendoza, M., Rubio, H., Banales, J.L., Granados, J. Increase of unidentified HLA antigens in pulmonary tuberculosis. Ann. Clin. Res. 17, 40\u201342 (1985)."},{"issue":"5","key":"290_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1399-0039.1978.tb01275.x","volume":"11","author":"R Selby","year":"1978","unstructured":"Selby, R. et al. Tuberculosis associated with HLA\u2013B8, BfS in a Newfoundland community study. Tissue Antigens 11(5), 403\u2013408. https:\/\/doi.org\/10.1111\/j.1399-0039.1978.tb01275.x (1978).","journal-title":"Tissue Antigens"},{"key":"290_CR13","unstructured":"Ferreira, E., Ward, F. E. & Amos, D. B. HL-A in a Brazilian population: evidence for new HL-A specificities. Histocompatibility Testing 1975, pp. 226\u2013230. Munksgaard, Copenhagen. (1975)."},{"issue":"4","key":"290_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1034\/j.1399-0039.2001.057004308.x","volume":"57","author":"A Arnaiz-Villena","year":"2001","unstructured":"Arnaiz-Villena, A. et al. HLA alleles and haplotypes in the Turkish population: Relatedness to Kurds, Armenians and other mediterraneans. Tissue Antigens 57(4), 308\u2013317. https:\/\/doi.org\/10.1034\/j.1399-0039.2001.057004308.x (2001).","journal-title":"Tissue Antigens"},{"issue":"2","key":"290_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1164\/arrd.1985.132.2.382","volume":"132","author":"CH Hwang","year":"1985","unstructured":"Hwang, C. H. et al. The HLA-A, -B, and -DR phenotypes and tuberculosis. Am. Rev. Respir Dis. 132(2), 382\u2013385. https:\/\/doi.org\/10.1164\/arrd.1985.132.2.382 (1985).","journal-title":"Am. Rev. Respir Dis."},{"key":"290_CR16","doi-asserted-by":"publisher","first-page":"D423","DOI":"10.1093\/nar\/gku1161","volume":"43","author":"J Robinson","year":"2015","unstructured":"Robinson, J. et al. The IPD and IPD-IMGT\/HLA database: Allele variant databases. Nucleic Acid Res. 43, D423\u2013D431 (2015).","journal-title":"Nucleic Acid Res."},{"issue":"4","key":"290_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/1346-8138.12071","volume":"40","author":"H Mortazavi","year":"2013","unstructured":"Mortazavi, H. et al. Association of human leukocyte antigen class I antigens in Iranian patients with pemphigus vulgaris. J. Dermatol. 40(4), 244\u2013248. https:\/\/doi.org\/10.1111\/1346-8138.12071 (2013).","journal-title":"J. Dermatol."},{"issue":"2","key":"290_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1399-0039.2004.00258.x","volume":"64","author":"FA Uyar","year":"2004","unstructured":"Uyar, F. A., Dorak, M. T. & Saruhan-Direskeneli, G. Human leukocyte antigen-A, -B and -C alleles and human leukocyte antigen haplotypes in Turkey: Relationship to other populations. Tissue Antigens 64(2), 180\u2013187. https:\/\/doi.org\/10.1111\/j.1399-0039.2004.00258.x (2004).","journal-title":"Tissue Antigens"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00290-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:27:33Z","timestamp":1745972853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00290-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00290-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5419969\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"9 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics committee approval was obtained from Gaziantep University Ethics Committee. Ethical approval was obtained with this number and date (https:\/\/doi.org\/10-2011\/182, 25\/10\/2011).Written informed consent was obtained from all patients included in the study. Patients signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"15152"}}